CNBC Healthy Returns (July 8): Employer GLP-1 Coverage for Obesity Held Steady at 36% Year-Over-Year Despite Medicare GLP-1 Bridge Launch on July 1 — 60% of Employers Cover GLP-1s for Diabetes Only, 3% Don't Cover, 2% Unsure; 27% of Employers Steer Workers to Direct-to-Consumer Cash Platforms, 21% Push FSA/HSA/HRA Spending; Uninsured Share for Zepbound Rose 18% Year-Over-Year, Leaving 114 Million Americans With No Commercial Coverage for the Drug
CNBC Healthy Returns and the Peterson Health Technology Institute (PHTI) documented Wednesday July 8, 2026 that employer coverage of GLP-1 drugs for obesity has held steady at 36% year-over-year despite the Medicare GLP-1 Bridge launching on July 1 and putting downward pressure on the payer landscape. Mercer survey data shows 60% of employers cover GLP-1s for diabetes only, 36% cover for both diabetes and weight loss, 3% don't cover them at all, and 2% are not sure. Rather than expanding coverage, employers pursued alternative approaches: 27% steer workers to direct-to-consumer cash platforms (such as LillyDirect, NovoCare Pharmacy, and telehealth intermediaries), while 21% push workers to use FSA, HSA, or integrated HRA dollars. GoodRx data show the uninsured share for Zepbound rose 18% year-over-year, leaving over 114 million Americans with no commercial coverage for the drug; 88% of those who do have coverage face additional requirements like prior authorization. GLP-1 drugs accounted for 11.4% of annual claims for employers covering them in 2026, up from 6.9% in 2023, sustaining the affordability tension that has kept coverage stuck.